Summit Therapeutics (SMMT) Appoints Robert Booth to its Board

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/16/2026

1. NVDA
2. CRWV
3. SPY
4. BAC
5. BLK
6. CAT
7. AA
8. RKLB
9. FMC
10. MRSH

Go back to Summit Therapeutics (SMMT) Appoints Robert Booth to its Board

Summit Therapeutics Appoints Dr. Robert Booth, Renowned Executive and Scientific Leader, to its Board of Directors

October 3, 2022 4:36 PM EDT

Menlo Park, California, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced that Dr. Robert Booth, PhD, has been appointed to its Board of Directors, effective immediately.

Dr. Booth initiated the BTK inhibitor program at Celera Genomics, Inc. that ultimately became Pharmacyclics, Inc.s IMBRUVICA® (ibrutinib), the blockbuster drug that changed the paradigm of treatment for many hematological cancers.

Our world class executives and leaders at Team Summit continue to demonstrate our convening power in our ability to attract such a stellar... More